Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic biopsy study of ianalumab in Sjögren's syndrome
2020-005055-20Phase 2Active
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Primary endpoint: Change from baseline in logarithm of salivary gland B/B+T cell ratio at Week 25. Started Nov 2021; status: active.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2020-005055-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005055-20.